Tumour markers: Their use and misuse by clinicians

Annals of Clinical Biochemistry

Volumn 40, Issue 6, 2003, Pages 643-647

  McGinley, Peter J ^a   Kilpatrick, Eric S ^a  

^a HULL ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; CA 125 ANTIGEN; CA 15-3 ANTIGEN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CHORIONIC GONADOTROPIN; PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOPSY; COMPUTER; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENERAL PRACTICE; GOOD LABORATORY PRACTICE; HOSPITAL ADMISSION; HUMAN; INFORMATION PROCESSING; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TEACHING HOSPITAL; TUMOR;

AGED; FEMALE; HEALTH SERVICES MISUSE; HUMANS; LONGITUDINAL STUDIES; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PROSTATE-SPECIFIC ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0242721648     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/000456303770367234     Document Type: Article

References (23)

1. Hanning I, Dow E. Tumour markers. Surgery 1998; 16: iii-v
2. Duffy M, McGing P, McSweeny J. Guidelines for the Use of Tumour Markers. Association of Clinical Biochemists in Ireland, 2000 www.iol.ie/~deskenny/acbi- tmk.html (last accessed September 2003)
3. Sturgeon C. Practice guidelines for tumour marker use in the clinic. Clin Chem 2002; 48: 1151-9
4. Gorgoulis V, Tiniakos D, Mariatos G, Manolis E, Mitropoulos D, Kittas C. Recent advances in early prostatic cancer. Anticancer Res 1999; 19: 2327-48
5. Blijenberg B, Storm B, Van Zelst B, Boeken Kruger A, Schroder F. New developments in the standardisation of prostate specific antigen. Clin Biochem 1999; 32: 627-34
6. Farley K. Ovarian cancer early detection program. Oncol Nurs Forum 1999; 26: 833-4
7. Kroll M. Prostate cancer: free PSA adds value to PSA testing. Clin Lab News 2002; 4: 10-1
8. European Society for Medical Oncology. ESMO minimum clinical recommendations for diagnosis, adjuvant treatment and follow-up of colon cancer. Ann Oncol 2001; 12: 1053-4
9. Bell R. Screening for ovarian cancer: is it worth the risk? Nurs Times 1999; 95: 52-3
10. Maxwell P. Carcinoembryonic antigen: cell adhesion molecule and useful diagnostic marker. Br J Biomed Sci 1999; 56: 209-14
11. Urban N. Screening for ovarian cancer: we now need a definitive randomised trial. BMJ 1999; 319: 1317-8
12. Rhodes J. Usefulness of novel tumour markers. Ann Oncol 1999; 4: S118-S121
13. Konety B, Getzenberg R. Urine based markers of urological malignancy. J Urol 2001; 165: 600-11
14. Kim J-H, Skates S, Uede T, Wong K-W, Schorge J, Feltmate C. Osteopontin as a potential biomarker for ovarian cancer. JAMA 2002; 287; 1671-9
15. Ikinara O, Cheli C, Partin A, Fritche H, Chan D, Sokoll L. Comparative analysis of complexed prostate-specific antigen, free prostate-specific antigen and their ratio in detecting prostate cancer. J Urol 2002; 167: 2017-24
16. Rustin G, Nelstrop A, Betzen S, Piccart M, Bertelsen K. Use of tumour markers in monitoring the course of ovarian cancer. Ann Oncol 1999; 10: S21-S27
17. Erbagci B, Yilmaz N, Kutlar I. Menstrual cycle dependent variability for serum tumour markers CEA, AFP, CA19-9, CA125 and CA15-3 in healthy women. Dis Markers 1999; 15: 259-67
18. Khalifa A, Mady E, Abadeer N, Kamal A. Differential tumour markers and hepatitis markers profile in liver tumours. Anticancer Res 1999; 19: 2495-500
19. Bon G, Kenemans P, Dekker J, Hompes P, Verstraeten R, van Kamp G. Fluctuations in CA125 and CA15-3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod 1999; 14: 566-70
20. Brett J, Watson E, Bukah C, Austoker J. PSA Testing for Prostate Cancer. An information sheet for men considering a PSA test. Cancer Research UK Primary Care Education Research Group, 2002 www.dphpc.ox.ac.uk/crcpcerg/research/ resprostate.htm (last accessed September 2003)
21. Krishnan S, Philipose Z, Rayman G. Hypothyroidism mimicking intra-abdominal malignancy. BMJ 2002; 325: 946-7
22. Lamm D. The challenge of improved diagnostic and prognostic indicators of superficial bladder cancer. J Urol 2000; 164: 690-1
23. Jacobs I, Skates S, MacDonald N, Menon U, Rosenthal A, Prys Davis A. Outcome of a pilot randomised controlled trial of ovarian cancer screening. Lancet 1999; 253: 1207-10